Gemcitabine With Curcumin for Pancreatic Cancer

Phase 2

Completed

• Conditions: Pancreatic Cancer

• Registration Number: NCT00192842
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-16
• Study First Posted: 2005-09-19
• Primary Completion: 2007-11
• Status Verified: 2010-09
• Study Completion: 2010-09
• Last Update Submitted: 2010-09-21
• Last Update Posted: 2010-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• locally advanced or metastatic adenocarcinoma of the pancreas
• no prior chemotherapy
• performance status 0-2
• adequate hematology and chemistry

Exclusion Criteria

• serious concurrent medical condition

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
time to tumor progression

Secondary Outcome Measures

Name	Time	Method
response rate
survival
clinical benefit
toxicity